Arcturus Therapeutics Holdings Inc (ARCT)

$35.28

-0.93

(-2.57%)

Market is closed - opens 8 PM, 22 Feb 2024

Insights on Arcturus Therapeutics Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 9.56M → 43.37M (in $), with an average increase of 78.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -52.55M → -16.22M (in $), with an average increase of 223.9% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 273.3%

Performance

  • $34.53
    $35.70
    $35.28
    downward going graph

    2.13%

    Downside

    Day's Volatility :3.28%

    Upside

    1.18%

    downward going graph
  • $14.21
    $41.68
    $35.28
    downward going graph

    59.72%

    Downside

    52 Weeks Volatility :65.91%

    Upside

    15.36%

    downward going graph

Returns

PeriodArcturus Therapeutics Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
49.94%
11.5%
0.0%
6 Months
8.19%
9.2%
0.0%
1 Year
100.68%
12.0%
-6.6%
3 Years
-40.8%
27.4%
-21.4%

Highlights

Market Capitalization
967.7M
Book Value
$10.48
Earnings Per Share (EPS)
3.69
PE Ratio
9.81
Wall Street Target Price
65.25
Profit Margin
33.53%
Operating Margin TTM
-42.79%
Return On Assets TTM
10.24%
Return On Equity TTM
46.66%
Revenue TTM
296.2M
Revenue Per Share TTM
11.16
Quarterly Revenue Growth YOY
237.6%
Gross Profit TTM
62.9M
EBITDA
64.2M
Diluted Eps TTM
3.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.78
EPS Estimate Next Year
-3.29
EPS Estimate Current Quarter
-1.69
EPS Estimate Next Quarter
-1.19

Analyst Recommendation

Buy
    86%Buy
    6%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Arcturus Therapeutics Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 84.95%

Current $35.28
Target $65.25

Company Financials

FY18Y/Y Change
Revenue
15.8M
↑ 21.2%
Net Income
-21.8M
↑ 99.83%
Net Profit Margin
-138.29%
↓ 54.42%
FY19Y/Y Change
Revenue
20.8M
↑ 31.97%
Net Income
-25.7M
↑ 18.07%
Net Profit Margin
-123.72%
↑ 14.57%
FY20Y/Y Change
Revenue
9.5M
↓ 54.12%
Net Income
-71.4M
↑ 177.45%
Net Profit Margin
-748.13%
↓ 624.41%
FY21Y/Y Change
Revenue
12.4M
↑ 29.56%
Net Income
-206.9M
↑ 189.87%
Net Profit Margin
-1.7K%
↓ 925.65%
FY22Y/Y Change
Revenue
205.8M
↑ 1564.82%
Net Income
9.3M
↓ 104.52%
Net Profit Margin
4.54%
↑ 1678.32%
FY23Y/Y Change
Revenue
292.7M
↑ 42.27%
Net Income
99.3M
↑ 962.46%
Net Profit Margin
33.93%
↑ 29.39%
Q2 FY22Q/Q Change
Revenue
27.1M
↑ 416.65%
Net Income
-21.0M
↓ 59.51%
Net Profit Margin
-77.65%
↑ 913.18%
Q3 FY22Q/Q Change
Revenue
13.4M
↓ 50.66%
Net Income
-34.5M
↑ 64.0%
Net Profit Margin
-258.07%
↓ 180.42%
Q4 FY22Q/Q Change
Revenue
160.0M
↑ 1097.17%
Net Income
117.3M
↓ 440.13%
Net Profit Margin
73.32%
↑ 331.39%
Q1 FY23Q/Q Change
Revenue
79.7M
↓ 50.18%
Net Income
50.8M
↓ 56.75%
Net Profit Margin
63.66%
↓ 9.66%
Q2 FY23Q/Q Change
Revenue
9.6M
↓ 88.0%
Net Income
-52.6M
↓ 203.54%
Net Profit Margin
-549.4%
↓ 613.06%
Q3 FY23Q/Q Change
Revenue
43.4M
↑ 353.49%
Net Income
-16.2M
↓ 69.13%
Net Profit Margin
-37.4%
↑ 512.0%
FY17Y/Y Change
Total Assets
52.0M
↑ 0.88%
Total Liabilities
18.2M
↑ 320.05%
FY18Y/Y Change
Total Assets
44.2M
↓ 15.04%
Total Liabilities
30.6M
↑ 67.61%
FY19Y/Y Change
Total Assets
82.1M
↑ 85.85%
Total Liabilities
56.4M
↑ 84.42%
FY20Y/Y Change
Total Assets
476.5M
↑ 480.03%
Total Liabilities
79.9M
↑ 41.8%
FY21Y/Y Change
Total Assets
392.8M
↓ 17.56%
Total Liabilities
164.6M
↑ 106.0%
FY22Y/Y Change
Total Assets
450.4M
↑ 14.66%
Total Liabilities
180.1M
↑ 9.4%
Q2 FY22Q/Q Change
Total Assets
337.0M
↓ 1.45%
Total Liabilities
166.3M
↑ 5.76%
Q3 FY22Q/Q Change
Total Assets
293.6M
↓ 12.87%
Total Liabilities
148.0M
↓ 11.03%
Q4 FY22Q/Q Change
Total Assets
450.4M
↑ 53.39%
Total Liabilities
180.1M
↑ 21.71%
Q1 FY23Q/Q Change
Total Assets
470.9M
↑ 4.55%
Total Liabilities
141.6M
↓ 21.36%
Q2 FY23Q/Q Change
Total Assets
430.6M
↓ 8.54%
Total Liabilities
145.5M
↑ 2.72%
Q3 FY23Q/Q Change
Total Assets
457.7M
↑ 6.27%
Total Liabilities
177.6M
↑ 22.08%
FY18Y/Y Change
Operating Cash Flow
-20.8M
↑ 4413.04%
Investing Cash Flow
22.1M
↑ 113.75%
Financing Cash Flow
10.2M
↑ 45.81%
FY19Y/Y Change
Operating Cash Flow
-6.4M
↓ 68.95%
Investing Cash Flow
-818.0K
↓ 103.7%
Financing Cash Flow
41.9M
↑ 310.69%
FY20Y/Y Change
Operating Cash Flow
-42.9M
↑ 565.03%
Investing Cash Flow
-1.7M
↑ 112.96%
Financing Cash Flow
436.1M
↑ 940.74%
FY21Y/Y Change
Operating Cash Flow
-135.0M
↑ 215.07%
Investing Cash Flow
-3.4M
↑ 95.52%
Financing Cash Flow
48.0M
↓ 88.99%
FY22Y/Y Change
Operating Cash Flow
32.0M
↓ 123.69%
Investing Cash Flow
-7.7M
↑ 126.83%
Financing Cash Flow
-2.9M
↓ 105.95%
Q2 FY22Q/Q Change
Operating Cash Flow
-36.8M
↓ 24.91%
Investing Cash Flow
378.0K
↓ 117.91%
Financing Cash Flow
257.0K
↓ 23.51%
Q3 FY22Q/Q Change
Operating Cash Flow
-42.4M
↑ 15.17%
Investing Cash Flow
-2.2M
↓ 678.31%
Financing Cash Flow
-1.2M
↓ 574.71%
Q4 FY22Q/Q Change
Operating Cash Flow
160.3M
↓ 477.92%
Investing Cash Flow
-354.0K
↓ 83.81%
Financing Cash Flow
-2.2M
↑ 82.95%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.9M
↓ 122.38%
Investing Cash Flow
-691.0K
↑ 95.2%
Financing Cash Flow
-27.4M
↑ 1125.99%
Q2 FY23Q/Q Change
Operating Cash Flow
50.8M
↓ 241.64%
Investing Cash Flow
-354.0K
↓ 48.77%
Financing Cash Flow
94.0K
↓ 100.34%

Technicals Summary

Sell

Neutral

Buy

Arcturus Therapeutics Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
3.34%
8.19%
100.68%
-40.8%
408.36%
Moderna, Inc.
Moderna, Inc.
-12.15%
-24.65%
-44.62%
-45.04%
340.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.06%
13.35%
27.37%
106.88%
125.51%
Novo Nordisk A/s
Novo Nordisk A/s
14.64%
30.73%
70.02%
232.45%
385.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.65%
19.76%
42.56%
95.21%
125.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
9.81
9.81
NA
-1.78
0.47
0.1
NA
10.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.5
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.43
27.43
1.93
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
44.55
44.55
4.4
3.29
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.28
30.28
0.57
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
Buy
$967.7M
408.36%
9.81
33.53%
Moderna, Inc.
Moderna, Inc.
Buy
$33.7B
340.59%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$104.7B
125.51%
27.43
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$548.5B
385.86%
44.55
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$108.7B
125.9%
30.28
36.68%

Institutional Holdings

  • Federated Hermes Inc

    17.63%
  • BlackRock Inc

    8.00%
  • ARK Investment Management LLC

    7.12%
  • State Street Corporation

    6.24%
  • Vanguard Group Inc

    5.26%
  • Sumitomo Mitsui Trust Holdings Inc

    5.20%

Company Information

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Organization
Arcturus Therapeutics Holdings Inc
Employees
170
CEO
Mr. Joseph E. Payne M.Sc.
Industry
Health Technology

FAQs